Home
Companies
Catalysts
Deep Dives
Kisunla
donanemab
APPROVED
Drug Profile
Modality
Antibody
Route
IV
Therapy Area
Neurology
Launch
2024-07-02
US LOE
2036-07-01
Peak Sales Est
$5000M
Formulations
[{"id":"kisunla-iv","notes":"Unique stopping rule: discontinue when amyloid cleared on PET","route":
Companies
LLY
(ORIGINATOR)
100%
Mechanism: Amyloid-beta clearance
Expert:
Monoclonal antibody targeting N-terminal pyroglutamate amyloid-beta (N3pG Aβ), promoting clearance of amyloid plaques via microglial phagocytosis.
Everyday:
An antibody that clears toxic protein clumps (amyloid plaques) from the brain, potentially slowing Alzheimer's progression.
Targets: ["AMYLOID-BETA"]
Revenue History
Period
Revenue ($M)
Q3 2024
$50M
Programs (1)
Indication
Stage
Key Study
Regional Status
AD
APPROVED
TRAILBLAZER-ALZ 2
[{"stage":"APPROVED","region":"US","label_notes":"Early symptomatic AD with conf
Upcoming Catalysts (1)
Donanemab - Preclinical AD - Ph3 - Interim (TRAILBLAZER-ALZ 3)
2027+
Notes
Unique stop-dosing protocol once plaques cleared
Data from Supabase · Updated 2026-03-24